Krystal Biotech (KRYS) Assets (2016 - 2026)
Krystal Biotech (KRYS) posted quarterly Assets of $1.5 billion for Q2 2026, up 31.82% year-over-year from $1.1 billion in Q2 2025, and up 7.42% on a QoQ basis from $1.4 billion in Q1 2026.
Krystal Biotech (KRYS) Assets (2016 - 2026) Analysis & Trends
Krystal Biotech has reported Assets for 11 years, with the latest figure at $1.5 billion in Q2 2026.
- Assets for Q2 2026 came in at $1.5 billion, up 31.82% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 31.82% YoY), and the FY2025 annual result was $1.3 billion, up 26.33% from the prior year.
- Assets rose to $1.5 billion in Q2 2026, from $1.4 billion in the prior quarter.
- Over five years, Assets peaked at $1.5 billion in Q2 2026 and troughed at $531.8 million in Q1 2023.
- A 5-year average of $926.2 million and a median of $885.5 million in 2024 frame the typical range for Assets.
- The widest annual swing landed in 2023, when Assets decreased 13.78%; it then surged 60.44% in 2024.
- A 5-year view of Assets shows it stood at $558.4 million in 2022, then jumped by 46.54% to $818.4 million in 2023, then advanced by 29.02% to $1.1 billion in 2024, then increased by 26.33% to $1.3 billion in 2025, then increased by 12.51% to $1.5 billion in 2026.
- Per Business Quant data, the three most recent Assets figures were $1.5 billion in Q2 2026, $1.4 billion in Q1 2026, and $1.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 1.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Bn |
| Mar 31, 2026 | 1.40 Bn |
| Dec 31, 2025 | 1.33 Bn |
| Sep 30, 2025 | 1.24 Bn |
| Jun 30, 2025 | 1.14 Bn |
| Mar 31, 2025 | 1.07 Bn |
| Dec 31, 2024 | 1.06 Bn |
| Sep 30, 2024 | 982.32 Mn |
| Jun 30, 2024 | 917.66 Mn |
| Mar 31, 2024 | 853.30 Mn |
| Dec 31, 2023 | 818.36 Mn |
| Sep 30, 2023 | 790.35 Mn |
| Jun 30, 2023 | 684.03 Mn |
| Mar 31, 2023 | 531.85 Mn |
| Dec 31, 2022 | 558.45 Mn |
| Sep 30, 2022 | 576.38 Mn |
| Jun 30, 2022 | 601.32 Mn |
| Mar 31, 2022 | 616.87 Mn |
| Dec 31, 2021 | 626.30 Mn |
| Sep 30, 2021 | 451.10 Mn |